Deficit of osteoprotegerin release by osteoblasts from a patient with cystic fibrosis

European Respiratory Journal

Volumn 39, Issue 3, 2012, Pages 780-781

  Gimenez Maitre, A ^a   Le Henaff, C ^a   Norez, C ^c   Guillaume, C ^a   Ravoninjatovo, B ^b   Laurent Maquin, D ^a   Becq, F ^c   Jacquot, J ^a  

^a INSERM   (France)

^b REIMS UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE POITIERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; MESSENGER RNA; OSTEOPROTEGERIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; TUMOR NECROSIS FACTOR ALPHA;

AGE DISTRIBUTION; BONE DENSITY; BONE DISEASE; BONE MINERALIZATION; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE; DISEASE ASSOCIATION; DISEASE SEVERITY; HUMAN; LETTER; MUTATIONAL ANALYSIS; OSTEOBLAST; OSTEOLYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; REGULATOR GENE;

ADENYLATE CYCLASE; ADULT; CELLS, CULTURED; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FORSKOLIN; GENISTEIN; HUMANS; MALE; OSTEOBLASTS; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84860230604     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00104111     Document Type: Letter

References (10)

1. Haworth CS. Impact of cystic fibrosis on bone health. Curr Opin Pulm Med 2010; 16: 616-622.
2. Sermet-Gaudelus I, Castanet M, Retsch-Bogart G, et al. Update on cystic fibrosis-related bone disease: a special focus on children. Paediatr Respir Rev 2009; 10: 134-142.
3. Shead EF, Haworth CS, Condliffe AM, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone. Thorax 2007; 62: 650-651. (Pubitemid 47056896)
4. Le Heron L, Guillaume C, Velard F, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) regulates the production of osteoprotegerin (OPG) and prostaglandin (PG) E(2) in human bone. J Cyst Fibros 2010; 9: 69-72.
5. King SJ, Topliss DJ, Kotsimbos T, et al. Reduced bone density in cystic fibrosis: DF508 mutation is an independent risk factor. Eur Respir J 2005; 25: 54-61. (Pubitemid 40207731)
6. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-319. (Pubitemid 27199902)
7. Grundt A, Grafe IA, Liegibel U, et al. Direct effects of osteoprotegerin on human bone cell metabolism. Biochem Biophys Res Commun 2009; 389: 550-555.
8. Norez C, Antigny F, Noel S, et al. A cystic fibrosis respiratory epithelial cell chronically treated by miglustat acquires a non-cystic fibrosis-like phenotype. Am J Respir Cell Mol Biol 2009; 41: 217-225.
9. Haston CK, Li W, Li A, et al. Persistent osteopenia in adult cystic fibrosis transmembrane conductance regulator-deficient mice. Am J Respir Crit Care Med 2008; 177: 309-315. (Pubitemid 351198374)
10. Shead EF, Haworth CS, Barker H, et al. Osteoclast function, bone turnover and inflammatory cytokines during infective exacerbations of cystic fibrosis. J Cyst Fibros 2010; 9: 93-98.